Exchange: NASDAQ·Updated 07:30 PM EDT

DFTX News

News
all
press releases
DFTX Stock Climbs As High As 12% On ‘Unprecedented’ Anxiety Data For LSD-Based Drug
The company said that the Panorama trial of DT120, a fast-dissolving tablet form of the psychedelic drug lysergide, or LSD, met its main goal in adults with generalized anxiety disorder.
Stocktwits
More News
Definium Says Its Anxiety Drug Showed 'Unprecedented Efficacy'
Definium Therapeutics announced positive Phase 3 Panorama trial results for DT120 in generalized anxiety disorder patients.read more...
Benzinga
Five Stories Putting Traders on Notice: Insider Buying, FDA Catalysts, Psychedelic Breakthroughs and a U.S. Tungsten Rush
The market is once again rewarding investors willing to look beyond the headline indexes; NeOnc Technologies Holdings (NASDAQ:NTHI), Armata Pharmaceuticals (NYSEAMERICAN:ARMP), Definium Therapeutics (NASDAQ:DFTX), Basel Medical Group (NASDAQ:BMGL), Blue Moon Metals (NASDAQ:BMM) and The Elmet Group (NASDAQ:ELMT).
24-7 Market News
Futures Slide As Tech Tumbles On Fears Of AI Slowdown, Oil Jumps
Futures Slide As Tech Tumbles On Fears Of AI Slowdown, Oil Jumps US futures are sliding, dragged by fears of a possible AI development slowdown as well as higher oil prices (Brent > 108), though bond yields are not reacting yet (10Y yield still under 5%). As of 8:00am ET, S&P futures...
Zero Hedge
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 44.6% to $2.4 during Monday's pre-market session. The company's market cap stands at $1.1 million. Definium Therapeutics (NASDAQ:DFTX)read more...
Benzinga
Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder
Definium Therapeutics, Inc. (Nasdaq: DFTX) (Definium or the Company), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced positive topline results from Panorama...
Business Wire
DFTX Stock Jumps Overnight As Investors Brace For Phase 3 Results From LSD-Based Anxiety Drug
Investors are awaiting topline results from Panorama, its second Phase 3 trial of DT120 in generalized anxiety disorder, set to be unveiled on Monday.
Stocktwits
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Companys...
Business Wire
This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Top analysts changed outlook on top names. See analyst ratings page for all changes.read more...
Benzinga
Notable Wednesday Option Activity: DFTX, MSGS, TPR
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Definium Therapeutics Inc (Symbol: DFTX), where a total volume of 14,758 contracts has been traded thus far today, a contract volume which is representative of a...
Nasdaq News: Markets

Advertisement|Remove ads.